Wright 2019 Allergy.pdf (512.73 kB)
Download file

Mepolizumab does not alter the blood basophil count in severe asthma.

Download (512.73 kB)
journal contribution
posted on 24.07.2019, 13:28 by AKA Wright, S Diver, J McCarthy, A Marvin, M Soares, T Thornton, M Bourne, M Craner, H Evans, S Edwards, S Glover, L Carr, S Parker, S Siddiqui, D Cousins, C Brightling
[First paragraph] To the Editor: Mepolizumab (anti‐IL‐5) depletes blood and airway eosinophils, and, clinically, allows down‐titration of oral corticosteroid and a reduction in the frequency of eosinophil‐dependent exacerbations.1 Basophils also express IL‐5Rα, participate in T2‐mediated inflammatory pathways2 and have been associated with exacerbation frequency.3 Whilst basophil progenitors are unlikely to depend on IL‐5 for development,4 blood basophil counts measured in routine clinical laboratories suggest they decrease following mepolizumab treatment.5-8

Funding

This research was funded by Leicester Drug Discovery and Diagnostics (LD3) with financial contributions from MRC grant MC_PC_15045 and supported by the NIHR Leicester Biomedical Research Centre.

History

Citation

Allergy, 2019

Author affiliation

/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Department of Infection, Immunity and Inflammation

Version

VoR (Version of Record)

Published in

Allergy

Publisher

Wiley

eissn

1398-9995

Copyright date

2019

Available date

24/07/2019

Publisher version

https://onlinelibrary.wiley.com/doi/full/10.1111/all.13879

Notes

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Language

en

Usage metrics

Categories

Keywords

Licence

Exports